Raymond James & Associates Boosts Stock Position in Repligen Co. (NASDAQ:RGEN)

Raymond James & Associates boosted its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 49.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 82,277 shares of the biotechnology company's stock after purchasing an additional 27,158 shares during the quarter. Raymond James & Associates owned approximately 0.15% of Repligen worth $12,244,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of RGEN. Thrivent Financial for Lutherans boosted its position in shares of Repligen by 240.5% during the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock valued at $75,866,000 after acquiring an additional 425,061 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock valued at $172,749,000 after buying an additional 237,884 shares during the period. Conestoga Capital Advisors LLC raised its holdings in Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock valued at $119,363,000 after buying an additional 199,322 shares during the period. Dimensional Fund Advisors LP raised its holdings in Repligen by 39.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company's stock valued at $54,149,000 after buying an additional 121,305 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in Repligen by 494.0% during the 1st quarter. BNP Paribas Financial Markets now owns 80,399 shares of the biotechnology company's stock valued at $14,787,000 after buying an additional 66,864 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Up 1.3 %

RGEN stock traded up $1.76 during trading on Monday, reaching $137.21. 389,630 shares of the company traded hands, compared to its average volume of 663,480. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The business has a 50 day simple moving average of $143.45 and a 200 day simple moving average of $146.83. The company has a market capitalization of $7.69 billion, a price-to-earnings ratio of -3,385.65, a price-to-earnings-growth ratio of 3.91 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts' consensus estimates of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. During the same quarter last year, the company earned $0.53 earnings per share. The firm's revenue for the quarter was down 3.2% compared to the same quarter last year. On average, equities research analysts anticipate that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the topic of several recent research reports. Stephens restated an "overweight" rating and set a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. Wells Fargo & Company began coverage on Repligen in a research note on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 target price on the stock. Benchmark reiterated a "hold" rating on shares of Repligen in a research note on Monday, August 5th. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Wednesday, July 31st. Finally, Royal Bank of Canada restated an "outperform" rating and set a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Repligen has an average rating of "Moderate Buy" and a consensus price target of $190.25.

Insiders Place Their Bets

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Anthony Hunt sold 22,191 shares of the firm's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the firm's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now owns 19,261 shares of the company's stock, valued at approximately $3,190,969.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.